These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 23406016)

  • 1. Combining phenotypic and proteomic approaches to identify membrane targets in a 'triple negative' breast cancer cell type.
    Rust S; Guillard S; Sachsenmeier K; Hay C; Davidson M; Karlsson A; Karlsson R; Brand E; Lowne D; Elvin J; Flynn M; Kurosawa G; Hollingsworth R; Jermutus L; Minter R
    Mol Cancer; 2013 Feb; 12():11. PubMed ID: 23406016
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative characterisation of an ecto-5'-nucleotidase (CD73) in non-tumoral MCF10-A breast cells and triple-negative MDA-MB-231 breast cancer cells.
    Rocha-Vieira TC; Lacerda-Abreu MA; Carvalho-Kelly LF; Santos-Araújo S; Gondim KC; Meyer-Fernandes JR
    Cell Biol Int; 2024 Sep; 48(9):1354-1363. PubMed ID: 38894528
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of anti-tumour biologics using primary tumour models, 3-D phenotypic screening and image-based multi-parametric profiling.
    Sandercock AM; Rust S; Guillard S; Sachsenmeier KF; Holoweckyj N; Hay C; Flynn M; Huang Q; Yan K; Herpers B; Price LS; Soden J; Freeth J; Jermutus L; Hollingsworth R; Minter R
    Mol Cancer; 2015 Jul; 14():147. PubMed ID: 26227951
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Novel Specific Anti-CD73 Antibody Inhibits Triple-Negative Breast Cancer Cell Motility by Regulating Autophagy.
    Qiao Z; Li X; Kang N; Yang Y; Chen C; Wu T; Zhao M; Liu Y; Ji X
    Int J Mol Sci; 2019 Feb; 20(5):. PubMed ID: 30823477
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Growth and molecular interactions of the anti-EGFR antibody cetuximab and the DNA cross-linking agent cisplatin in gefitinib-resistant MDA-MB-468 cells: new prospects in the treatment of triple-negative/basal-like breast cancer.
    Oliveras-Ferraros C; Vazquez-Martin A; López-Bonet E; Martín-Castillo B; Del Barco S; Brunet J; Menendez JA
    Int J Oncol; 2008 Dec; 33(6):1165-76. PubMed ID: 19020749
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tiamulin inhibits breast cancer growth and pulmonary metastasis by decreasing the activity of CD73.
    Yang X; Pei S; Wang H; Jin Y; Yu F; Zhou B; Zhang H; Zhang D; Lin D
    BMC Cancer; 2017 Apr; 17(1):255. PubMed ID: 28399915
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gonadotropin-releasing hormone type II antagonist induces apoptosis in MCF-7 and triple-negative MDA-MB-231 human breast cancer cells in vitro and in vivo.
    Gründker C; Föst C; Fister S; Nolte N; Günthert AR; Emons G
    Breast Cancer Res; 2010; 12(4):R49. PubMed ID: 20630060
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting triple-negative breast cancer cells with the histone deacetylase inhibitor panobinostat.
    Tate CR; Rhodes LV; Segar HC; Driver JL; Pounder FN; Burow ME; Collins-Burow BM
    Breast Cancer Res; 2012 May; 14(3):R79. PubMed ID: 22613095
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Proteomic profiling of triple-negative breast carcinomas in combination with a three-tier orthogonal technology approach identifies Mage-A4 as potential therapeutic target in estrogen receptor negative breast cancer.
    Cabezón T; Gromova I; Gromov P; Serizawa R; Timmermans Wielenga V; Kroman N; Celis JE; Moreira JM
    Mol Cell Proteomics; 2013 Feb; 12(2):381-94. PubMed ID: 23172894
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CIP2A is a target of bortezomib in human triple negative breast cancer cells.
    Tseng LM; Liu CY; Chang KC; Chu PY; Shiau CW; Chen KF
    Breast Cancer Res; 2012 Apr; 14(2):R68. PubMed ID: 22537901
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of everolimus, a novel mTOR inhibitor, against basal-like triple-negative breast cancer cells.
    Yunokawa M; Koizumi F; Kitamura Y; Katanasaka Y; Okamoto N; Kodaira M; Yonemori K; Shimizu C; Ando M; Masutomi K; Yoshida T; Fujiwara Y; Tamura K
    Cancer Sci; 2012 Sep; 103(9):1665-71. PubMed ID: 22703543
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Extracellular 5'-nucleotidase (CD73) promotes human breast cancer cells growth through AKT/GSK-3β/β-catenin/cyclinD1 signaling pathway.
    Yu J; Wang X; Lu Q; Wang J; Li L; Liao X; Zhu W; Lv L; Zhi X; Yu J; Jin Y; Zou Q; Ou Z; Liu X; Zhou P
    Int J Cancer; 2018 Mar; 142(5):959-967. PubMed ID: 29047106
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Knock-out of CD73 delays the onset of HR-negative breast cancer by reprogramming lipid metabolism and is associated with increased tumor mutational burden.
    Serafin PK; Popęda M; Bulak K; Zwara A; Galikowska-Bogut B; Przychodzka A; Mika A; Śledziński T; Stanisławowski M; Jendernalik K; Bolcewicz M; Laprus W; Stasiłojć G; Sądej R; Żaczek A; Kalinowski L; Koszałka P
    Mol Metab; 2024 Nov; 89():102035. PubMed ID: 39304062
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasma membrane proteomics identifies bone marrow stromal antigen 2 as a potential therapeutic target in endometrial cancer.
    Yokoyama T; Enomoto T; Serada S; Morimoto A; Matsuzaki S; Ueda Y; Yoshino K; Fujita M; Kyo S; Iwahori K; Fujimoto M; Kimura T; Naka T
    Int J Cancer; 2013 Jan; 132(2):472-84. PubMed ID: 22729361
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 'Triple negative' epithelial ovarian cancer and pathologic markers for prognosis.
    Liu N; Wang X; Sheng X
    Curr Opin Obstet Gynecol; 2011 Feb; 23(1):19-23. PubMed ID: 21150601
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potential prognostic biomarker CD73 regulates epidermal growth factor receptor expression in human breast cancer.
    Zhi X; Wang Y; Yu J; Yu J; Zhang L; Yin L; Zhou P
    IUBMB Life; 2012 Nov; 64(11):911-20. PubMed ID: 23086814
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-human CD73 monoclonal antibody inhibits metastasis formation in human breast cancer by inducing clustering and internalization of CD73 expressed on the surface of cancer cells.
    Terp MG; Olesen KA; Arnspang EC; Lund RR; Lagerholm BC; Ditzel HJ; Leth-Larsen R
    J Immunol; 2013 Oct; 191(8):4165-73. PubMed ID: 24043904
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel antitumor activity of deguelin targeting the insulin-like growth factor (IGF) receptor pathway via up-regulation of IGF-binding protein-3 expression in breast cancer.
    Suh YA; Kim JH; Sung MA; Boo HJ; Yun HJ; Lee SH; Lee HJ; Min HY; Suh YG; Kim KW; Lee HY
    Cancer Lett; 2013 May; 332(1):102-9. PubMed ID: 23348700
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Establishment of a bioluminescent MDA-MB-231 cell line for in vivo imaging of human triple-negative breast cancer xenograft].
    Wang K; Xie SM; He JJ; Ren Y; Xia HB; Zhang XW
    Nan Fang Yi Ke Da Xue Xue Bao; 2011 Nov; 31(11):1812-8. PubMed ID: 22126756
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel approach for targeted elimination of CSPG4-positive triple-negative breast cancer cells using a MAP tau-based fusion protein.
    Amoury M; Mladenov R; Nachreiner T; Pham AT; Hristodorov D; Di Fiore S; Helfrich W; Pardo A; Fey G; Schwenkert M; Thepen T; Kiessling F; Hussain AF; Fischer R; Kolberg K; Barth S
    Int J Cancer; 2016 Aug; 139(4):916-27. PubMed ID: 27037627
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.